149 related articles for article (PubMed ID: 22202100)
21. Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo.
Medin JA; Liang SB; Hou JW; Kelley LS; Peace DJ; Fowler DH
Cancer Gene Ther; 2005 Jun; 12(6):540-51. PubMed ID: 15678150
[TBL] [Abstract][Full Text] [Related]
22. Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression.
Krupa M; Canamero M; Gomez CE; Najera JL; Gil J; Esteban M
Vaccine; 2011 Feb; 29(7):1504-13. PubMed ID: 21182993
[TBL] [Abstract][Full Text] [Related]
23. Current perspectives in prostate cancer vaccines.
Arlen PM; Gulley JL
Anticancer Agents Med Chem; 2009 Dec; 9(10):1052-7. PubMed ID: 19719454
[TBL] [Abstract][Full Text] [Related]
24. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival.
Thomas-Kaskel AK; Zeiser R; Jochim R; Robbel C; Schultze-Seemann W; Waller CF; Veelken H
Int J Cancer; 2006 Nov; 119(10):2428-34. PubMed ID: 16977630
[TBL] [Abstract][Full Text] [Related]
25. Humoral immune response in prostate cancer patients after immunization with gene-based vaccines that encode for a protein that is proteasomally degraded.
Todorova K; Ignatova I; Tchakarov S; Altankova I; Zoubak S; Kyurkchiev S; Mincheff M
Cancer Immun; 2005 Jan; 5():1. PubMed ID: 15641767
[TBL] [Abstract][Full Text] [Related]
26. DNA vaccines for the treatment of prostate cancer.
Alam S; McNeel DG
Expert Rev Vaccines; 2010 Jul; 9(7):731-45. PubMed ID: 20624047
[TBL] [Abstract][Full Text] [Related]
27. Update on prostate cancer vaccines.
Drake CG
Cancer J; 2011; 17(5):294-9. PubMed ID: 21952278
[TBL] [Abstract][Full Text] [Related]
28. Cancer immunotherapy based on recombinant Salmonella enterica serovar Typhimurium aroA strains secreting prostate-specific antigen and cholera toxin subunit B.
Fensterle J; Bergmann B; Yone CL; Hotz C; Meyer SR; Spreng S; Goebel W; Rapp UR; Gentschev I
Cancer Gene Ther; 2008 Feb; 15(2):85-93. PubMed ID: 18084243
[TBL] [Abstract][Full Text] [Related]
29. Prostate-specific membrane antigen vaccines: naked DNA and protein approaches.
Slovin SF
Clin Prostate Cancer; 2005 Sep; 4(2):118-23. PubMed ID: 16197613
[TBL] [Abstract][Full Text] [Related]
30. DNA vaccine for cancer immunotherapy.
Yang B; Jeang J; Yang A; Wu TC; Hung CF
Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapeutics in development for prostate cancer.
Harzstark AL; Small EJ
Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
[TBL] [Abstract][Full Text] [Related]
32. Progress in active specific immunotherapy of prostate cancer.
Tjoa BA; Murphy GP
Semin Surg Oncol; 2000; 18(1):80-7. PubMed ID: 10617899
[TBL] [Abstract][Full Text] [Related]
33. Construction of a fusion plasmid containing the PSCA gene and cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and its anti-tumor effect in an animal model of prostate cancer.
Mai TJ; Ma R; Li Z; Bi SC
Braz J Med Biol Res; 2016 Oct; 49(11):e5620. PubMed ID: 27783810
[TBL] [Abstract][Full Text] [Related]
34. Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer.
Simms MS; Scholfield DP; Jacobs E; Michaeli D; Broome P; Humphreys JE; Bishop MC
Br J Cancer; 2000 Aug; 83(4):443-6. PubMed ID: 10945488
[TBL] [Abstract][Full Text] [Related]
35. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer.
Sanda MG; Smith DC; Charles LG; Hwang C; Pienta KJ; Schlom J; Milenic D; Panicali D; Montie JE
Urology; 1999 Feb; 53(2):260-6. PubMed ID: 9933036
[TBL] [Abstract][Full Text] [Related]
36. Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer.
Miller AM; Ozenci V; Kiessling R; Pisa P
J Immunother; 2005; 28(4):389-95. PubMed ID: 16000958
[TBL] [Abstract][Full Text] [Related]
37. Dramatic and prolonged PSA response after retreatment with a PSA vaccine.
Rojan A; Funches R; Regan MM; Gulley JL; Bubley GJ
Clin Genitourin Cancer; 2013 Sep; 11(3):362-4. PubMed ID: 23791437
[No Abstract] [Full Text] [Related]
38. A novel DNA/peptide combined vaccine induces PSCA-specific cytotoxic T-lymphocyte responses and suppresses tumor growth in experimental prostate cancer.
Zhang KQ; Yang F; Ye J; Jiang M; Liu Y; Jin FS; Wu YZ
Urology; 2012 Jun; 79(6):1410.e7-13. PubMed ID: 22513035
[TBL] [Abstract][Full Text] [Related]
39. Vaccines versus immunotherapy: overview of approaches in deciding between options.
Dalgleish AG
Hum Vaccin Immunother; 2014; 10(11):3369-74. PubMed ID: 25625932
[TBL] [Abstract][Full Text] [Related]
40. Formulation of the bivalent prostate cancer vaccine with surgifoam elicits antigen-specific effector T cells in PSA-transgenic mice.
Karan D
Vaccine; 2017 Oct; 35(43):5794-5798. PubMed ID: 28939158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
